Foundation Medicine has appointed Gary Palmer to senior vice president of medical affairs and commercial development, a newly created position. In this role, Palmer will lead the commercialization of the company's tests as it moves into the field of personalized cancer treatment based on whole-genome sequence data.
Palmer is a medical oncologist with thirty years' experience in the oncology field. Prior to Foundation Medicine, he served as chief medical officer and head of development for DNA repair marker development and circulating tumor cell technology for On-Q-ity. He also served as vice president of medical affairs at Genomic Health and held leadership positions at Amgen.
He holds a BA from Yale University, an MD from Stanford University School of Medicine, an MBA from the University of California, Davis, an MPH from the University of California, Los Angeles, and a JD from Concord University.
PerkinElmer, which recently launched a next-gen sequencing service (see story, this issue) has announced its sequencing and analysis team.
Richard Begley is the president of emerging technologies. Begley has been at PerkinElmer since 2007. Previously he was the president and CEO of Ensemble Discovery, and also served as president and CEO of 454 Life Sciences. He holds a BS in physics from Fordham University, as well as an MS and PhD in applied physics and an MBA from Stanford University.
Gerard Irzyk is the senior director of operations for emerging technologies, a role he has held since June 2010. He is responsible for running the sequencing and bioinformatics analysis center, as well as evaluating new software, instrumentation, and process improvements. Prior to joining PerkinElmer, he was the director of the 454 Sequencing Center at 454 Life Sciences, and managed operations at Curagen's sequencing facility. He holds multiple degrees from Purdue University, including a PhD in plant physiology.
Karen Madden joined PerkinElmer in September 2010 as the senior director of business development in emerging technologies. Previously Madden managed corporate development and external research activities at VisEn Medical. She has also held leadership roles at FeinsteinKean Healthcare and Kendall Strategies. She holds an MS from the University of Pennsylvania and a PhD in chemistry from Rutgers University.
Christopher Mapel, who joined the company in August 2010, is the director of global sales and collaborations. He has also held positions at Dionex, DeCode Genetics, Applied Biosystems, Celera, Gene Logic, Solexa, Illumina, and NanoString Technologies. He holds a BS in biology from the University of Cincinnati.
William Spencer, who joined the company in September 2009, is the senior director of emerging technologies and program manager for the sequencing and analysis services business. Previously, he held roles at BD Biosciences, Applied Biosystems, 454 Life Sciences, and OpGen. He holds a BS in biology and chemistry from Bowling Green State University.
Edward Szekeres joined PerkinElmer in June 2010 and is the director of bioinformatics for sequencing and analysis services. He previously held roles at 454 Life Sciences and Curagen. He was also the owner and operator of FES Digital Solutions and a clinical microbiologist at Strong Memorial Hospital. He holds a BA in neurobiology from Cornell University, and an MS and PhD in biophysics from the University of Rochester Medical School.